{"disease":{"id":"mesothelioma-malignant","name":"mesothelioma malignant"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05910112","title":"Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT05429866","title":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":441,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT03762018","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":false},{"nct_id":"NCT05245500","title":"Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04334759","title":"DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"PrECOG, LLC.","has_results":false},{"nct_id":"NCT05308966","title":"Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)","phase":"","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Groupe Francais De Pneumo-Cancerologie","has_results":false},{"nct_id":"NCT05278975","title":"Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"RS Oncology LLC","has_results":false},{"nct_id":"NCT03654833","title":"Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"University of Leicester","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT02991482","title":"PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02357147","title":"Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":124,"lead_sponsor_name":"Morphotek","has_results":true},{"nct_id":"NCT01064648","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05136677","title":"A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06566079","title":"Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"InSilico Medicine Hong Kong Limited","has_results":false},{"nct_id":"NCT06946498","title":"First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National and Kapodistrian University of Athens","has_results":false},{"nct_id":"NCT04177953","title":"Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT05455424","title":"Niraparib Efficacy in Patient With Unresectable Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT05324436","title":"A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)","phase":"","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04491942","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02399371","title":"Pembrolizumab in Treating Patients With Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06057935","title":"A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06886672","title":"Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03907852","title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"TCR2 Therapeutics","has_results":false},{"nct_id":"NCT06637345","title":"Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)","phase":"","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT06281860","title":"Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":39,"lead_sponsor_name":"Dr Jean Yannis PERENTES","has_results":false},{"nct_id":"NCT03507452","title":"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03502746","title":"Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"Arkadiusz Z. Dudek, MD","has_results":true},{"nct_id":"NCT04823741","title":"Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05380713","title":"......SMARTEST Trial......","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07126509","title":"Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT02535312","title":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03228537","title":"Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04400539","title":"The IMmunotherapy Pleural 5-ALA PDT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT04158141","title":"Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT05500508","title":"Oral AMXT 1501 Dicaprate in Combination With IV DFMO","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Aminex Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03420963","title":"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02408016","title":"Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06299163","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Numab Therapeutics AG","has_results":false},{"nct_id":"NCT03393858","title":"Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT05960773","title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05451849","title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"TCR2 Therapeutics","has_results":false},{"nct_id":"NCT02062632","title":"Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02672033","title":"Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma","phase":"NA","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT04213794","title":"Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06654050","title":"Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05375825","title":"Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}